December 14, 2020
A number of Karyopharm Therapeutics Inc.'s board members and executives are targeted in a shareholder's derivative lawsuit filed Monday in Massachusetts federal court accusing them of having a hand in misleading investors about clinical trials relating to a blood cancer treatment.